You are here

  • Home
  • Archive
  • Volume 79, Issue 6
  • Correction: Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)

Article Text

Article menu

Download PDFPDF

XML
Miscellaneous
Correction: Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)

https://doi.org/10.1136/annrheumdis-2019-216118corr1

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Dougados M, Wei JC-C, Landewé R, et al. Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W). Ann of Rheum Dis 2020;79:176-85.

    The numbers in table 1 and supplementary Table 3 were inadvertently sourced from outdated documents. The correct details are shown as:

    View this table:
    Table 1

    Week 16* and 52 efficacy endpoints for patients treated continuously with ixekizumab: COAST-V and COAST-W (ITT population: NRI, modified baseline observation carried forward)

    View this table:
    Table 3

    Week 16 and 52 efficacy endpoints for patients treated continuously with ixekizumab: COAST-V and COAST-W (ITT population: observed data)